Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

But now that these drugs are in greater demand from both patients and doctors, state Medicaid programs are grappling with whether to cover them for weight loss, both for reasons of equity and to save ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...